Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: Post hoc analysis of REACT
Alimentary Pharmacology and Therapeutics Mar 23, 2019
Singh S, et al. - In a post hoc analysis of the randomised evaluation of an algorithm for Crohn's treatment (REACT), a cluster-randomised trial, researchers assessed the effect of age on the risk of Crohn's disease-related complications in patients treated with early combined immunosuppression vs conventional management. For this post hoc analysis, at the time of enrollment in the trial, patients were classified as younger (<60 years) or older (≥60 years, population of interest). In older and younger patients, no difference was found in the effectiveness and safety of early combined immunosuppression vs conventional management. In selected older patients with Crohn's disease with suboptimal disease control, early combined immunosuppression may be considered as a treatment option.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries